Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Nexviazyme® (avalglucosidase alfa-ngpt) – New orphan drug approval

The FDA announced the approval of Sanofi’s Nexviazyme (avalglucosidase alfa-ngpt), for the treatment of patients 1 year of age and older with late-onset Pompe disease (LOPD) [lysosomal acid alpha-glucosidase (GAA) deficiency]. August 6, 2021

Duexis® (ibuprofen/famotidine) – First-time generic

Alkem launched an AB-rated generic version of Horizon’s Duexis (ibuprofen/famotidine) tablets. August 4, 2021

Istodax® (romidepsin) – Indication withdrawal

Bristol-Myers Squibb (BMS) announced that the company plans to voluntarily withdraw the indication for Istodax (romidepsin) as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. August 2, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.